Last 7 days
-5.7%
Last 30 days
-17.1%
Last 90 days
-23.4%
Trailing 12 Months
-31.2%
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 0 | 0 | 0 | 0 |
2022 | 41.1M | 63.2M | 85.3M | 107.4M |
2021 | 0 | 0 | 0 | 18.9M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jun 30, 2023 | trigilio jeffrey | acquired | 21,247 | 9.08 | 2,340 | chief financial officer |
Jun 28, 2023 | ahmed nadim | sold | -8,652 | 11.4 | -759 | president and ceo |
Jun 20, 2023 | jones jeffrey alan | sold | -5,007 | 12.94 | -387 | chief medical officer |
Jun 20, 2023 | sumer jacquelyn l | sold | -3,765 | 12.94 | -291 | chief legal officer |
Jun 20, 2023 | michaelson jennifer | sold | -3,079 | 12.94 | -238 | chief development officer |
Jun 20, 2023 | trigilio jeffrey | sold | -5,163 | 12.94 | -399 | chief financial officer |
Jun 12, 2023 | michaelson jennifer | sold | -2,307 | 13.11 | -176 | chief development officer |
Jun 12, 2023 | trigilio jeffrey | sold | -4,182 | 13.11 | -319 | chief financial officer |
Jun 07, 2023 | michaelson jennifer | sold | -1,240 | 12.4 | -100 | chief development officer |
Jun 07, 2023 | michaelson jennifer | acquired | 430 | 4.3 | 100 | chief development officer |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Nov 24, 2023 | DEUTSCHE BANK AG\ | reduced | -44.33 | -47,449 | 41,784 | -% |
Nov 21, 2023 | COMERICA BANK | new | - | 1,105 | 1,105 | -% |
Nov 17, 2023 | JACOBS LEVY EQUITY MANAGEMENT, INC | sold off | -100 | -901,096 | - | -% |
Nov 15, 2023 | JANE STREET GROUP, LLC | reduced | -69.17 | -429,424 | 150,357 | -% |
Nov 15, 2023 | MORGAN STANLEY | reduced | -12.82 | -933,021 | 2,564,920 | -% |
Nov 15, 2023 | Rubric Capital Management LP | unchanged | - | -1,072,050 | 5,673,710 | 0.21% |
Nov 15, 2023 | Annandale Capital, LLC | added | 20.00 | 1,000 | 109,000 | 0.03% |
Nov 15, 2023 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | sold off | -100 | -53,000 | - | -% |
Nov 15, 2023 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | unchanged | - | -18,283 | 96,763 | -% |
Nov 15, 2023 | Baker Avenue Asset Management, LP | unchanged | - | -82.00 | 434 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Sep 07, 2023 | blackrock inc. | 4.8% | 2,036,651 | SC 13G/A | |
Feb 15, 2023 | jovan-embiricos morana | 3.4% | 1,577,440 | SC 13G/A | |
Feb 14, 2023 | biotechnology value fund l p | 8.9% | 4,058,854 | SC 13G/A | |
Feb 13, 2023 | chi advisors llc | 7.25% | 3,317,544 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 6.15% | 2,812,965 | SC 13G/A | |
Feb 03, 2023 | blackrock inc. | 5.5% | 2,506,215 | SC 13G | |
Feb 14, 2022 | biotechnology value fund l p | 6.4% | 2,790,018 | SC 13G/A | |
Feb 11, 2022 | foresite capital fund v, l.p. | 2.6% | 1,143,006 | SC 13G/A | |
Feb 11, 2022 | chi advisors llc | 5.67% | 2,476,720 | SC 13G | |
Feb 09, 2022 | vanguard group inc | 5.42% | 2,366,808 | SC 13G |
Date Filed | Form Type | Document | |
---|---|---|---|
Nov 08, 2023 | 8-K | Current Report | |
Nov 08, 2023 | 10-Q | Quarterly Report | |
Sep 07, 2023 | SC 13G/A | Major Ownership Report |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
HILS | 31.4B | - | 4.92% | 426363.59% | -3.6K | 218.4K | - | -102.45% |
MRNA | 30.7B | 10.7B | 11.84% | -53.56% | -8.86 | 2.88 | -53.67% | -129.46% |
ALNY | 22.0B | 1.7B | 4.71% | -20.32% | -43.06 | 12.74 | 79.37% | 56.87% |
BMRN | 17.7B | 2.3B | 23.54% | -7.88% | 120.62 | 7.68 | 15.05% | 75.21% |
INCY | 12.4B | 3.6B | 1.56% | -32.86% | 29.22 | 3.44 | 8.35% | -51.49% |
MID-CAP | ||||||||
APLS | 7.5B | 272.9M | 38.55% | 34.32% | -12.3 | 27.31 | 141.38% | 4.43% |
BBIO | 5.6B | - | 16.25% | 246.63% | -9.66 | 48.33 | 54.84% | -12.96% |
ACAD | 3.5B | 631.9M | -10.80% | 43.56% | -23.57 | 5.55 | 23.54% | 31.53% |
AXSM | 3.3B | 223.4M | 11.07% | -7.88% | -16.25 | 14.68 | - | -26.24% |
ARWR | 2.6B | 240.7M | -11.66% | -25.68% | -12.44 | 10.6 | -1.03% | -16.59% |
SMALL-CAP | ||||||||
CPRX | 1.5B | 348.4M | 7.85% | -14.88% | 24.07 | 4.29 | 81.69% | -7.29% |
NVAX | 662.5M | 1.0B | -19.01% | -66.75% | -1.21 | 0.63 | -43.15% | 58.48% |
INO | 100.5M | 6.4M | -2.56% | -78.77% | -0.61 | 15.6 | -44.11% | 50.48% |
IBIO | 42.3M | - | 410.00% | -4.38% | -0.65 | - | - | -29.23% |
CRBP | 26.3M | - | 17.86% | 4717.52% | -0.55 | - | - | -13.74% |
Income Statement (Quarterly) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 |
Revenue | - | - | - | - | - | - | 173,566,000 | 86,783,000 | - | - | - | 18,943,000 |
Operating Expenses | 19.1% | 44,803,000 | 37,605,000 | 62,756,000 | 32,608,000 | 29,766,000 | 37,106,000 | 32,657,000 | 34,347,000 | 18,375,000 | 16,604,000 | 17,571,000 |
S&GA Expenses | 7.5% | 10,982,000 | 10,214,000 | 10,660,000 | 11,287,000 | 10,086,000 | 10,695,000 | 8,121,000 | 13,469,000 | 5,695,000 | 4,826,000 | 5,156,000 |
R&D Expenses | 23.5% | 33,821,000 | 27,391,000 | 52,096,000 | 21,321,000 | 19,680,000 | 26,411,000 | 24,536,000 | 20,878,000 | 12,680,000 | 11,778,000 | 12,415,000 |
EBITDA Margin | - | - | - | 1.17 | 1.41 | 0.74 | 1.20 | -5.16 | -1.58 | -0.40 | - | - |
Income Taxes | - | - | - | - | -1,858,000 | -2,523,000 | 66,070,000 | -19,568,000 | - | - | - | - |
Earnings Before Taxes | -21.6% | -39,183,000 | -32,214,000 | -58,141,000 | -28,946,000 | -27,413,000 | 240,135,000 | -32,460,000 | -34,206,000 | -18,259,000 | -16,439,000 | 1,419,000 |
EBT Margin | - | - | - | 1.17 | 1.41 | 0.74 | 1.20 | -5.16 | -1.59 | -0.40 | - | - |
Net Income | -21.6% | -39,183,000 | -32,214,000 | -58,141,000 | -26,385,000 | -24,804,000 | 174,898,000 | -12,892,000 | -32,857,000 | -17,350,000 | -16,439,000 | 1,419,000 |
Net Income Margin | - | - | - | 0.60 | 1.04 | 0.52 | 0.33 | -4.10 | -3.46 | -0.81 | - | -0.33 |
Free Cashflow | - | - | - | -51,156,000 | -25,865,000 | -54,436,666 | - | -21,908,000 | -15,171,000 | -10,551,000 | -16,196,000 | -1,515,000 |
Balance Sheet | (In Millions) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Assets | -5.2% | 495 | 522 | 515 | 561 | 617 | 667 | 437 | 437 | 453 | 464 | 480 | 215 |
Current Assets | -4.3% | 477 | 498 | 399 | 474 | 582 | 623 | 322 | 297 | 329 | 344 | 447 | 212 |
Cash Equivalents | -54.3% | 65.00 | 142 | 122 | 156 | 243 | 354 | 76.00 | 60.00 | 88.00 | 124 | 294 | 168 |
Net PPE | -7.9% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | 15.5% | 26.00 | 22.00 | 29.00 | 26.00 | 31.00 | 63.00 | 18.00 | 12.00 | 8.00 | 6.00 | 10.00 | 14.00 |
Current Liabilities | 19.2% | 23.00 | 20.00 | 26.00 | 22.00 | 27.00 | 62.00 | 17.00 | 12.00 | 8.00 | 6.00 | 10.00 | 14.00 |
Shareholder's Equity | -6.2% | 469 | 500 | 486 | 535 | 586 | 605 | 419 | 425 | 445 | 459 | 470 | 200 |
Retained Earnings | -28.4% | -177 | -137 | -105 | -47.69 | -20.91 | 4.00 | -171 | -158 | -126 | -109 | -93.41 | -93.34 |
Additional Paid-In Capital | 1.2% | 647 | 639 | 593 | 585 | 611 | 604 | 593 | 585 | 570 | 565 | 560 | 292 |
Shares Outstanding | 0.1% | 43.00 | 43.00 | 39.00 | 46.00 | 46.00 | 45.00 | 44.00 | 44.00 | 43.00 | 43.00 | 42.00 | 30.00 |
Minority Interest | - | - | - | - | - | - | 0.00 | 1.00 | 0.00 | 2.00 | 3.00 | 3.00 | 1.00 |
Cashflow (Quarterly) | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Cashflow From Operations | -10.1% | -34,141,000 | -31,006,000 | -50,997,000 | -24,983,000 | -54,353,000 | -25,420,000 | -21,908,000 | -15,171,000 | -10,551,000 | -16,196,000 | -1,515,000 | -9,436,000 | -9,071,000 | -6,250,000 | -5,015,000 |
Share Based Compensation | -2.3% | 7,740,000 | 7,920,000 | 7,259,000 | 7,513,000 | 5,271,000 | 8,608,000 | 6,565,000 | 12,145,000 | 4,557,000 | 4,165,000 | 3,508,000 | - | - | - | - |
Cashflow From Investing | -454.7% | -42,958,000 | 12,110,000 | 15,184,000 | -28,610,000 | -57,978,000 | 300,852,000 | 34,711,000 | -15,862,000 | -25,593,000 | -154,594,000 | -137,726,000 | 11,440,000 | -1,941,000 | 11,971,000 | -26,890,000 |
Cashflow From Financing | -99.7% | 112,000 | 38,602,000 | 1,789,000 | -32,912,000 | 1,425,000 | 2,013,000 | 3,541,000 | 2,702,000 | 579,000 | 923,000 | 264,580,000 | 124,897,000 | 1,206,000 | - | 14,037,000 |
Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | 6,359,000 | - | - | 213,000 |
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Income Statement [Abstract] | ||||
Income (loss) from operations | $ (45,243) | $ (29,766) | $ (145,604) | $ 177,256 |
Operating expenses: | ||||
Research and development | 33,821 | 19,680 | 113,308 | 70,627 |
General and administrative | 10,982 | 10,086 | 31,856 | 28,902 |
Total operating expenses | 44,803 | 29,766 | 145,164 | 99,529 |
Gain on sale of Cullinan Pearl | 0 | 0 | 0 | 276,785 |
Impairment of long-lived assets | (440) | 0 | (440) | 0 |
Other income (expense): | ||||
Interest income | 5,880 | 2,353 | 15,710 | 3,247 |
Other income (expense), net | 180 | 0 | 356 | (241) |
Net income (loss) before income taxes | (39,183) | (27,413) | (129,538) | 180,262 |
Income tax expense (benefit) | 0 | (2,523) | 0 | 43,979 |
Net income (loss) | (39,183) | (24,890) | (129,538) | 136,283 |
Net loss attributable to noncontrolling interests | 0 | (86) | (179) | (1,713) |
Net income (loss) attributable to common stockholders of Cullinan | (39,183) | (24,804) | (129,359) | 137,996 |
Comprehensive income (loss): | ||||
Net income (loss) | (39,183) | (24,890) | (129,538) | 136,283 |
Unrealized gain on investments | 574 | (296) | 1,550 | (3,091) |
Comprehensive income (loss) | (38,609) | (25,186) | (127,988) | 133,192 |
Comprehensive loss attributable to noncontrolling interests | 0 | (86) | (179) | (1,713) |
Comprehensive income (loss) attributable to Cullinan | $ (38,609) | $ (25,100) | $ (127,809) | $ 134,905 |
Net income (loss) per share attributable to common stockholders of Cullinan: | ||||
Basic | $ (0.91) | $ (0.54) | $ (3.15) | $ 3.07 |
Diluted | $ (0.91) | $ (0.54) | $ (3.15) | $ 2.96 |
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders of Cullinan | ||||
Weighted-average common stock outstanding - basic | 42,734 | 45,611 | 41,130 | 44,966 |
Diluted | 42,734 | 45,611 | 41,130 | 46,580 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 64,847 | $ 156,152 |
Short-term investments | 401,583 | 311,140 |
Prepaid expenses and other current assets | 10,282 | 7,180 |
Total current assets | 476,712 | 474,472 |
Property and equipment, net | 1,066 | 1,174 |
Operating lease right-of-use assets | 2,925 | 4,130 |
Other assets | 459 | 459 |
Long-term investments | 13,545 | 80,882 |
Total assets | 494,707 | 561,117 |
Current liabilities: | ||
Accounts payable | 951 | 2,660 |
Accrued expenses and other current liabilities | 20,946 | 14,135 |
Income tax payable | 0 | 4,282 |
Operating lease liabilities, current | 1,547 | 1,421 |
Total current liabilities | 23,444 | 22,498 |
Long-term liabilities: | ||
Operating lease liabilities, net of current portion | 2,446 | 3,590 |
Total liabilities | 25,890 | 26,088 |
Commitments and contingencies (Note 11) | ||
Stockholders' equity: | ||
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 647,500 and no shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively | 0 | 0 |
Common stock, $0.0001 par value, 150,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 42,760,644 and 45,796,449 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively | 4 | 5 |
Additional paid-in capital | 646,918 | 585,320 |
Accumulated other comprehensive loss | (1,051) | (2,601) |
Accumulated deficit | (177,054) | (47,695) |
Total Cullinan stockholders' equity | 468,817 | 535,029 |
Noncontrolling interests | 0 | 0 |
Total stockholders' equity | 468,817 | 535,029 |
Total liabilities and stockholders' equity | $ 494,707 | $ 561,117 |
 CEO | Mr. Nadim Ahmed |
---|---|
 WEBSITE | www.cullinanoncology.com |
 EMPLOYEES | 62 |